TITLE:
A Study of Lobucavir in Patients With AIDS

CONDITION:
Cytomegalovirus Infections

INTERVENTION:
Lobucavir

SUMMARY:

      The purpose of this study is to see if lobucavir is a safe and effective treatment for
      cytomegalovirus in patients with AIDS.
    

DETAILED DESCRIPTION:

      Patients receive 1 of 2 doses of lobucavir for 28 days, with 2 weeks of follow-up. Weekly
      clinic visits are required.
    

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria

        Concurrent Medication:

        Allowed:

          -  Aerosolized pentamidine.

          -  TMP / SMX.

          -  Isoniazid.

          -  Dapsone.

          -  Fluconazole.

          -  Ketoconazole.

          -  Rifabutin.

          -  Fluoxetine HCl.

          -  Acetaminophen.

          -  Antacids.

          -  Metamucil.

          -  Multivitamins.

          -  Other drugs with approval from sponsor.

        Patients must have:

          -  AIDS.

          -  CD4 count < 200 cells/mm3.

          -  Cytomegalovirus ( CMV ) viruria and virosemenia.

          -  No evidence of intraocular CMV.

        Exclusion Criteria

        Co-existing Condition:

        Patients with the following symptoms or conditions are excluded:

          -  Acute or chronic cardiovascular, pulmonary, renal, hepatic, pancreatic, hematologic,
             endocrine, neurological, or other unstable illness.

          -  Inability to take oral medication.

          -  Allergy to nucleoside analogs.

          -  Diarrheal illness.

          -  Poor venous access.

          -  Positive test for drugs of abuse.

          -  Any other condition that would render patient unsuitable for study.

        Patients with the following prior conditions are excluded:

          -  History of pancreatitis.

          -  Recent diarrheal illness.

          -  History of weight loss.

          -  Acute serious illness within 4 weeks prior to study entry.

        Prior Medication:

        Excluded within 4 weeks prior to study entry:

          -  Erythropoietin.

          -  Any agent with anti-CMV activity.

          -  Other investigational agents.

        Prior Treatment:

        Excluded within 4 weeks prior to study entry:

          -  Surgery.

          -  Blood transfusion. Drug abuse.
      
